New global therapy now approved for Australian patients with Leiomyosarcoma
An additional chemotherapy option for people with advanced leiomyosarcoma is now available on the Pharmaceutical Benefits Scheme (PBS). Trabectedin, (brand name - Yondelis) offers renewed hope for patients facing this rare and challenging sarcoma cancer. [...]
















